PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Treating chronic hepatitis C with milk thistle extract does not appear beneficial

2012-07-18
(Press-News.org) CHICAGO – Use of the botanical product silymarin, an extract of milk thistle that is commonly used by some patients with chronic liver disease, did not provide greater benefit than placebo for patients with treatment-resistant chronic hepatitis C virus (HCV) infection, according to a study in the July 18 issue of JAMA.

Chronic hepatitis C virus infection affects almost 3 percent of the global population and may lead to cirrhosis, liver failure, and liver cancer. A large proportion of patients do not respond to certain treatments for this infection, and many others cannot be treated because of co-existing illnesses. "Thus, alternative medications with disease-modifying activity may be of benefit," according to background information in the article. Thirty-three percent of patients with chronic HCV infection and cirrhosis reported current or past use of silymarin for the treatment of their disease. Clinical studies that have evaluated milk thistle for a variety of liver diseases have yielded inconsistent results.

Michael W. Fried, M.D., of the University of North Carolina, Chapel Hill, and colleagues conducted a study to assess the use of silymarin for treating chronic HCV infection. The multicenter, placebo-controlled trial was conducted at 4 medical centers in the United States. Participants included 154 persons with chronic HCV infection and serum alanine aminotransferase (ALT; an enzyme that reflects liver function) levels of 65 U/L or greater who were previously unsuccessfully treated with interferon-based therapy. Enrollment began in May 2008 and was completed in May 2010, with the last follow-up visit completed in March 2011. Participants were randomly assigned to receive 420-mg silymarin, 700-mg silymarin, or matching placebo administered 3 times per day for 24 weeks. The primary outcome measure for the study was a serum ALT level of 45 U/L or less (considered within the normal range) or less than 65 U/L, provided this was at least a 50 percent decline from baseline values. Secondary outcomes included changes in ALT levels, HCV RNA levels, and quality-of-life measures.

At the end of treatment, only 2 participants in each treatment group achieved the prespecified primary end point. The percentages of participants who achieved the primary end point were 3.8 percent in the placebo group, 4.0 percent in the 420-mg silymarin group, and 3.8 percent in the 700-mg silymarin group. The researchers also found that there was no statistically significant difference across treatment groups when changes in serum ALT levels from the beginning of the study to end of treatment were analyzed. Also, average serum HCV RNA levels did not change significantly during the 24 weeks of therapy.

There were no significant changes in physical or mental health components of quality-of-life scores, in chronic liver disease health-related quality-of-life assessments, or in depression scores in any group. Frequency of adverse events reported by individual patients also did not differ significantly among the treatment groups.

"In summary, oral silymarin, used at higher than customary doses, did not significantly alter biochemical or virological markers of disease activity in patients with chronic HCV infection who had prior treatment with interferon-based regimens," the authors conclude.

###

(JAMA. 2012;308[3]:274-282. Available pre-embargo to the media at http://media.jamanetwork.com)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

To contact Michael W. Fried, M.D., call Tom Hughes at 919-966-6047 or email tahughes@unch.unc.edu.

END



ELSE PRESS RELEASES FROM THIS DATE:

Stress fuels breast cancer metastasis to bone

2012-07-18
Stress can promote breast cancer cell colonization of bone, Vanderbilt Center for Bone Biology investigators have discovered. The studies, reported July 17 in PLoS Biology, demonstrate in mice that activation of the sympathetic nervous system – the "fight-or-flight" response to stress – primes the bone environment for breast cancer cell metastasis. The researchers were able to prevent breast cancer cell lesions in bone using propranolol, a cardiovascular medicine that inhibits sympathetic nervous system signals. Metastasis – the spread of cancer cells to distant organs, ...

Study examines variation, factors involved with patient-sharing networks among physicians in US

2012-07-18
CHICAGO – Physicians tend to share patients with colleagues who have similar personal traits and practice styles, and there is substantial variation in physician network characteristics across geographic areas, according to a study in the July 18 issue of JAMA. Physicians are embedded in informal networks that result from their sharing of patients, information, and behaviors. "These informal information-sharing networks of physicians differ from formal organizational structures (such as a physician group associated with a health plan, hospital, or independent practice ...

Treatment of multiple sclerosis with interferon beta not linked with less progression of disability

2012-07-18
CHICAGO – Among patients with relapsing-remitting multiple sclerosis (MS), treatment with the widely-prescribed drug to treat MS, interferon beta, was not associated with less progression of disability, according to a study in the July 18 issue of JAMA. "A key feature of MS is clinical progression of the disease over time manifested by the accumulation of disability. Interferon beta drugs are the most widely prescribed disease-modifying drugs approved by the U.S. Food and Drug Administration for the treatment of relapsing-onset MS, the most common MS disease course," ...

Physicians' focus on risks for stroke and dementia saved lives, money

2012-07-18
Fewer people died or needed expensive long-term care when their physicians focused on the top risk factors for stroke and dementia, according to research reported in the Journal of the American Heart Association (JAHA). dementia The primary care doctors in the German study focused on high blood pressure, smoking, high cholesterol, diabetes, irregular heartbeat (atrial fibrillation) and depression. The researchers found that during a five-year period, the need for long-term care was cut 10 percent in women and 9.6 percent in men. Based on data collected in a comparison ...

Mammography screening shows limited effect on breast cancer mortality in Sweden

2012-07-18
Breast cancer mortality statistics in Sweden are consistent with studies that have reported that screening has limited or no impact on breast cancer mortality among women aged 40-69, according to a study published July 17 in the Journal of The National Cancer Institute. Since 1974, Swedish women aged 40-69 have increasingly been offered mammography screening, with nationwide coverage peaking in 1997. Researchers set out to determine if mortality trends would be reflected accordingly. In order to determine this, Philippe Autier, M.D., of the International Prevention ...

Penn expert addresses ethical implications of testing for Alzheimer's disease risk

2012-07-18
VANCOUVER – Diagnostic tests are increasingly capable of identifying plaques and tangles present in Alzheimer's disease, yet the disease remains untreatable. Questions remain about how these tests can be used in research studies examining potential interventions to treat and prevent Alzheimer's disease. Experts from the Perelman School of Medicine at the University of Pennsylvania will today participate in a panel at the Alzheimer's Association International Conference 2012 (AAIC 2012) discussing ways to ethically disclose and provide information about test results to asymptomatic ...

Modified tPA could be effective stroke treatment without bleeding risk

2012-07-18
Even when its clot-dissolving powers are removed, the stroke drug tPA can still protect brain cells from the loss of oxygen and glucose induced by a stroke, researchers have discovered. The finding suggests that a modified version of tPA could provide benefits to patients who have experienced a stroke, without increasing the risk of bleeding. The results will be published in the Journal of Neuroscience. "We may have been giving the right medication, for the wrong reason," says senior author Manuel Yepes, MD, associate professor of neurology at Emory University School ...

Stanford researchers calculate global health impacts of the Fukushima nuclear disaster

2012-07-18
Radiation from Japan's Fukushima Daiichi nuclear disaster may eventually cause anywhere from 15 to 1,300 deaths and from 24 to 2,500 cases of cancer, mostly in Japan, Stanford researchers have calculated. The estimates have large uncertainty ranges, but contrast with previous claims that the radioactive release would likely cause no severe health effects. The numbers are in addition to the roughly 600 deaths caused by the evacuation of the area surrounding the nuclear plant directly after the March 2011 earthquake, tsunami and meltdown. Recent PhD graduate John Ten ...

New way of mapping physicians provides valuable network science tool

2012-07-18
BOSTON – A new way of mapping how physicians share patients provides opportunities for improving the quality of medical care and organizing the nature of care delivery, according to researchers from Beth Israel Deaconess Medical Center and Harvard Medical School. In a study published in the July 18 edition of the Journal of the American Medical Association, researchers suggest this new way of systematically looking at how physicians are organized into patient-sharing networks can shed light on practice variation, aid in the spread of innovation and help form natural groups ...

Access to clinical trials drives dramatic increases in survival from childhood cancer

2012-07-18
More children are surviving cancer in Britain than ever before according to new research published in the cancer journal Annals of Oncology [1] today (Wednesday). The improvement in survival has been driven by the increasing numbers taking part in clinical trials since 1977 when the UK Children's Cancer Study Group (UKCCSG) [2] was established. The UKCCSG's principal aim was to set up a comprehensive portfolio of national and international trials for the majority of children's cancers. As result, between 1978 and 2005 two-thirds of children diagnosed with cancer in Britain ...

LAST 30 PRESS RELEASES:

University of Cincinnati experts present research at annual hematology event

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer

ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors

Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient

Continuous and fixed-duration treatments result in similar outcomes for CLL

Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia

Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease

Roughly one-third of families with children being treated for leukemia struggle to pay living expenses

Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy

IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection

Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients

Emergency departments fall short on delivering timely treatment for sickle cell pain

Study shows no clear evidence of harm from hydroxyurea use during pregnancy

Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease

Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia

Early results suggest exa-cel gene therapy works well in children

NTIDE: Disability employment holds steady after data hiatus

Social lives of viruses affect antiviral resistance

Dose of psilocybin, dash of rabies point to treatment for depression

Helping health care providers navigate social, political, and legal barriers to patient care

Barrow Neurological Institute, University of Calgary study urges “major change” to migraine treatment in Emergency Departments

Using smartphones to improve disaster search and rescue

Robust new photocatalyst paves the way for cleaner hydrogen peroxide production and greener chemical manufacturing

Ultrafast material captures toxic PFAS at record speed and capacity

Plant phenolic acids supercharge old antibiotics against multidrug resistant E. coli

UNC-Chapel Hill study shows AI can dramatically speed up digitizing natural history collections

OYE Therapeutics closes $5M convertible note round, advancing toward clinical development

Membrane ‘neighborhood’ helps transporter protein regulate cell signaling

Naval aviator turned NPS doctoral student earns national recognition for applied quantum research

[Press-News.org] Treating chronic hepatitis C with milk thistle extract does not appear beneficial